The impact of Alzheimer’s Disease is staggering – 6 million Americans diagnosed, a financial toll of $600 billion annually, and no effective drug treatments. ISB Co-founder Dr. Lee Hood said the traditional approach isn’t working, and we need to think about it in brand new ways.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
ISB’s compass has always been oriented toward the future. Even when we reflect on the past year for each annual report, it’s always through the lens of what’s on the horizon. We are remarkably consistent in that regard, which is in no small part due to our president Dr. Lee Hood, whose vision is perpetually a decade – at least – ahead of everyone else. In this year’s letter, Dr….
Institute for Systems Biology and Arivale “Pioneer 100 Study” Establishes Foundation for New Industry of Scientific Wellness. Personal, dense, dynamic data clouds enable novel insights into mechanisms of wellness and disease, new approaches to biomarker discovery, and the empowerment of individuals to enhance their own health.